News was built in to the rapid SP escalation already seen. I'm surprised the SP hasnt weakened more as the current result is as forecast, ie no upside surprise. A 2c divvy and no great expectation of further dramatic improvements means there is no compelling reason to buy into API at this time.
- Forums
- ASX - By Stock
- News: Australian Pharmaceutical swings to profit
News was built in to the rapid SP escalation already seen. I'm...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)